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ABSTRACT
Background: The gastrointestinal peptide hormone ghrelin was discovered in 1999 as the endogenous ligand of the growth hormone
secretagogue receptor. Increasing evidence supports more complicated and nuanced roles for the hormone, which go beyond the regulation of
systemic energy metabolism.
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Scope of review: In this review, we discuss the diverse biological functions of ghrelin, the regulation of its secretion, and address questions that
still remain 15 years after its discovery.
Major conclusions: In recent years, ghrelin has been found to have a plethora of central and peripheral actions in distinct areas including
learning and memory, gut motility and gastric acid secretion, sleep/wake rhythm, reward seeking behavior, taste sensation and glucose
metabolism.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1. INTRODUCTION
In 1999, Masayasu Kojima, Kenji Kangawa, and colleagues discovered
the gastrointestinal peptide hormone ghrelin as the endogenous ligand
for the growth hormone secretagogue receptor (GHSR)1a, capable of
stimulating growth hormone (GH) release from the anterior pituitary
gland [1]. In 2000, Mark Heiman and Matthias Tschöp discovered that
ghrelin acts in the brain to regulate food intake, body weight, adiposity,
and glucose metabolism [2]. Ghrelin was found to modulate systemic
metabolism via activation of orexigenic neural circuits [3,4]. Subse-
quently, numerous central and peripheral actions of ghrelin were
described, including stimulation of gut motility and gastric acid
secretion [5,6], modulation of sleep [7e9], taste sensation and reward
seeking behavior [10e16], regulation of glucose metabolism [17e20],
suppression of brown fat thermogenesis [21e25], modulation of
stress and anxiety [26e28], protection against muscle atrophy
[29,30], and improvement of cardiovascular functions such as vaso-
dilatation and cardiac contractility [31e34] (Figure 1).
In the early stages of ghrelin research, amodel emerged suggesting that
ghrelin acts as a “meal initiation” or “hunger“ hormone, signaling
gastrointestinal (GI) fuel status to the central nervous system (CNS) in
order to adjust food intake and energy expenditure [3,35e38].
Consistent with this role, ghrelin is produced in the oxyntic glands of the
gastric fundus [1], its blood levels rise with increased hunger sensations
[36,39], and its receptor is located in the hypothalamic neurons that
regulate food intake and satiety [40e42]. Recently, however, this
traditional and narrowly deﬁned view of ghrelin as a “hunger hormone”
has been challenged. Increasing evidence supports amore complex role
for ghrelin in the regulation of hunger and metabolism. The aim of this
review is to examine the variety of biological functions of ghrelin in order
to emphasize its multifaceted nature and to answer some questions that
persist after 15 years of ghrelin research.
2. DISCOVERY OF GHRELIN AS THE ENDOGENOUS LIGAND OF
THE GROWTH HORMONE SECRETAGOGUE RECEPTOR 1A
(GHSR1A)
In the late 1970s, the work of Cyril Bowers and Frank Momany led to
the generation of a group of synthetic opioid peptide derivatives that
promoted the release of GH from the anterior pituitary [43,44]. The
Figure 1: Schematic on ghrelin’s physiological effects.
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molecules, which Bowers and Momany referred to as GH releasing
peptides (GHRPs), were generated by the chemical modiﬁcation of
met-enkephalin and included growth hormone releasing peptide
(GHRP)-6, GHRP-2, and hexarelin [45]. Initially, it was thought that
these GHRPs acted only on the pituitary, but soon it became clear that
that they also acted on the hypothalamic arcuate nucleus (ARC) [46],
speciﬁcally on GH-releasing hormone (GHRH) neurons [41]. The
mechanism by which these molecules promoted the release of GH was
unknown, but it was distinct from that of the GHRH/somatostatin
pathway [46e49]. In 1996, the GHS clinical candidate MK0677 was
employed by Roy Smith and Lex van der Ploeg to clone the GH
secretagogue receptor (GHSR1a) [50], at which GHSs and GHRPs were
shown to be agonists.
In humans, the GHSR1 gene codes for the full-length G-protein coupled
seven transmembrane protein GHSR1a, but a truncated isoform
(GHSR1b), which has a wide tissue distribution, is also transcribed
[51]. GHSR1a has been shown to homodimerize, but the possibility has
been raised that GHSR1a and GHSR1b also heterodimerize [52,53] and
that the heterodimer inhibits the activation of GHSR1a [53].
GHSR1a is expressed predominantly in the anterior pituitary gland,
pancreatic islets, adrenal gland, thyroid, myocardium, ARC, hippocampus,
the substantia nigra pars compacta (SNpc), ventral tegmental area (VTA),
and raphe nuclei [40,51]. In the ARC, in addition to being expressed in
GHRH neurons, GHSR1a is colocalized in neurons that express neuro-
peptide Y (Npy) and Agouti related peptide (Agrp), which regulate food
intake and satiety [42]. Along with the observation that GHRP-6 induced
activation of GHSR1 and increased c-Fos expression in NPY neurons [41],
these data suggested the presence of an unknown but endogenous ligand
for GHSR1, one that might regulate systemic metabolism.
In the years that followed, extensive research efforts were aimed at
identifying the endogenous ligand for GHSR1. The ligand remained
elusive until 1999 when Kojima and colleagues identiﬁed the cognate
agonist for GHSR1. Puriﬁed from rat stomach extracts, the 28 amino
acid peptide was named ‘ghrelin’, a name originating from ‘ghre’, the
Proto-Indo-European root of the word ’grow’ [1].
3. REGULATION OF GHRELIN ACYLATION
3.1. Acylation of ghrelin by the ghrelin O-acyl-transferase (GOAT)
Ghrelin is encoded by the preproghrelin gene (Figure 2), which, in
addition to ghrelin, also encodes for a small signal peptide and the 23
amino acid peptide obestatin. Originally, it was thought that obestatin
Figure 2: Schematic on the post-translational processing and acylation of ghrelin.
MOLECULAR METABOLISM 4 (2015) 437e460  2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
439
was the endogenous ligand for GPR39 and could inhibit food intake and
gastric motility, functions that could counteract the effect of ghrelin
[54]. However, several independent groups could not conﬁrm these
ﬁndings and identiﬁed Zn2þ as a physiological agonist of GPR39 [55].
To activate its only known receptor, ghrelin requires the attachment of
a fatty acid side-chain (preferably C8 or C10) to its serine 3 residue, a
rare post-translational modiﬁcation (acylation) that is achieved by the
ghrelin O-acyl-transferase (GOAT), a member of the membrane-bound
O-acyltransferase (MBOAT) family [56,57] (Figure 2).
The discovery of GOAT as the enzyme responsible for ghrelin acylation
[56,57] has been a major breakthrough for understanding the role that
acyl-modiﬁcation plays in ghrelin’s physiology (Figure 3). This modi-
ﬁcation, mainly octanoylation and, to a lesser extent, decanoylation, is
required for ghrelin’s effects on systemic metabolism. The data
demonstrating GOAT’s essential role in the activation of ghrelin are
clear. First, GOAT and des-acyl ghrelin are sufﬁcient to recapitulate the
production of acyl-modiﬁed ghrelin in cells that normally do not ex-
press either of these gene products [56,57]. Second, ghrelin and GOAT
share a similar tissue expression proﬁles in both humans and mice
with highest GOAT expression in pancreas and stomach in humans and
the stomach and intestine in mice [56,58,59]. Third, GOAT, like ghrelin,
is highly conserved across vertebrates. Humans, rats, mice, and
zebraﬁsh all exhibit functional GOAT activity, and sequences with
amino acid similarities to GOAT are present in other vertebrates,
consistent with the presence of octanoylated forms of ghrelin across
vertebrates [56]. Finally, the most convincing data for GOAT as ghre-
lin’s acyl transferase are from GOAT-deﬁcient mice, which completely
lack octanoyl and decanoyl modiﬁed forms of ghrelin [20,56,60e62].
3.2. Substrates for GOAT-mediated ghrelin acylation
Intriguingly, the lipids used for ghrelin activation are, at least in part,
directly recruited from the pool of ingested dietary lipids [61,63] in a
process that may take advantage of the fact that ghrelin-producing X/
A-like cells are located within gastric oxyntic glands. A signiﬁcant
number of these cells are apposed to the stomach lumen, allowing for
direct access to a supply of dietary lipids [64]. Furthermore, the
preferred fatty acid substrates for GOAT are derived from medium-
chain-triglycerides, which can be directly absorbed into the circula-
tion without being broken down by lipases and bile acids [65]. Despite
this evidence, the relative contribution of de novo synthesized fatty
acids in comparison to those directly derived from the diet as substrate
of GOAT for ghrelin acylation remains unknown. Mutation studies in the
region of the acylated serine 3 have revealed that glycine 1, serine 3,
and phenylalanine 4 are critical components of the recognition
sequence for GOAT, whereas serine 2, leucine 5, serine 6 and proline 7
seem to be less important [62].
Biochemically, GOAT appears to have two critical substrates, des-acyl
ghrelin and short-to mid-chain fatty acids thioesteriﬁed with Coenzyme
A. Cells expressing both ghrelin and GOAT synthesize serine 3 acyl-
ghrelin, with the acyl moiety precursors derived from fatty acids
ranging from acetate (C2) to tetradecanoic acid (C14) [56]. The length
of the fatty acid used for ghrelin acylation seems to be of importance
for ghrelin’s metabolic effects, as alterations in the fatty acid length
result in differential activation of GHSR1a in vitro and alter ghrelin’s
effect on food intake and adiposity in vivo [66]. Thus, modulation of the
acyl side-chain may also represent an interesting therapeutic control
point for future interventions.
Octanoyl- and decanoyl-modiﬁed ghrelin forms are the optimal ligands
for activation of the GHSR1a [57,62]. In vitro studies recreating the
acyl-modiﬁcation of ghrelin with des-acyl ghrelin peptides, fatty acid
CoA esters, and GOAT containing microsomes deﬁne the substrate
speciﬁcity for GOAT. These studies support the idea that GOAT requires
fatty acid substrates as high energy fatty acid CoA thioesters and that
the amino acid sequence GXSFX, where G, X, S, and F correspond to
unblocked amino terminal glycine (G), any amino acid (X), serine (S)
and phenylalanine (F), respectively, is sufﬁcient as a substrate for
Figure 3: Milestones in ghrelin research. Bar graph represents the number of publications listed in the US National Library of Medicine National Institute of Health (PubMed) and
that contain the word ‘ghrelin’ in either the title or the abstract until December 2014.
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GOAT acylation [67]. The structural constraints deﬁned by this amino
acid motif appear speciﬁc only for ghrelin and suggest that ghrelin may
be the principal peptide substrate for GOAT. Most recent studies
comparing the in vitro selectivity of hexanoyl- and octanoyl-CoA sub-
strates suggest that GOAT may actually prefer hexanoyl CoA over
octanoyl CoA substrates, highlighting the importance of the speciﬁc
fatty acid metabolism in acyl ghrelin producing cells, responsible for
producing circulating levels of octanoyl and decanoyl ghrelin [67].
3.3. Evidence suggesting a role of the GOAT-ghrelin system as a
nutrient sensor
Most recent studies with genetically modiﬁed mice, which are either
lacking GOAT or overexpressing both ghrelin and GOAT, establish that
the GOAT-ghrelin system acts as a nutrient sensor informing the body
of the presence of nutrients, rather than the absence, as commonly
proposed [61]. Several observations support this statement. First,
prolonged fasting of mice led to well-established, increased levels of
total ghrelin, which were caused by increased des-acyl ghrelin rather
than acyl ghrelin. This increase in des-acyl ghrelin occurred as GOAT
transcript levels decreased in response to the prolonged fasting
treatments [61]. Consistent with these observations, GOAT-null mice
showed signiﬁcantly increased total ghrelin levels, being driven only by
des-acyl ghrelin as these mice are unable to produce acyl modiﬁed
ghrelin [56,61]. Second, several studies showed that dietary medium-
chain fatty acids (MCFAs) can be a direct source of substrates for
ghrelin acylation in rodents and that sensing of MCFAs involves the
gustatory G-protein, a-gustducin [61,63,68]. Third, studies also show
that mice lacking GOAT have lower body weight and fat mass on a
MCFA-containing diet compared to wt mice, whereas transgenic mice
overexpressing ghrelin and GOAT show higher body weight and fat
mass and decreased energy expenditure than wt littermates,
demonstrating a role for the endogenous acyl-ghrelin in the control of
energy balance and adiposity. In addition, data show that a sufﬁcient
dietary supply of medium chain triglycerides is crucial for ghrelin
acylation, since ghrelin and GOAT overexpressing mice are unable to
produce large amounts of octanoylated ghrelin when fed a low fat
carbohydrate-rich chow diet. Interestingly, transgenic mice fed a
regular chow diet show substantial amounts of inactive C2-acetyle
modiﬁed ghrelin in the absence of octanoylated ghrelin, suggesting
that, at least under these experimental conditions, the GOAT fatty acid
substrate for acylation, acetyl-CoA, is sufﬁciently available for ghrelin
acylation. Dietary supplementation of octanoyl triglycerides increases
octanoyl-modiﬁed ghrelin in these ghrelin and GOAT transgenic ani-
mals [61].
Based on these data, it is likely that the GOAT-ghrelin system acts as
a nutrient sensor by using readily absorbable MCFAs to signal to the
brain that high caloric food is available, leading to optimization of
nutrient partitioning and growth signals [61,63]. These recent
observations, while informative on the regulation of ghrelin’s func-
tion by GOAT, highlight key questions that need to be resolved. First,
are the observations on the role of GOAT and ghrelin in nutrient
sensing and the endocrine control of energy expenditure translatable
to humans? Second, what is the physiological role and what are key
players for this proposed acyl-ghrelin feedback mechanism observed
in the GOAT-deﬁcient animals? Finally, what is (are) the speciﬁc
biochemical pathway(s) in ghrelin and GOAT expressing cells that
produce the necessary levels of C8-CoAs critical for the synthesis of
physiologically relevant octanoylated ghrelin? Understanding these
fundamental aspects for ghrelin and GOAT will provide critical new
insights on the physiological function of this pathway on human
physiology.
4. BIOLOGICAL FUNCTIONS OF GHRELIN
4.1. Clinical pharmacology studies on ghrelin’s effect on energy
metabolism
Numerous human studies have evaluated the effect of ghrelin and its
analogs on GH secretion [69e72], food intake [11,34,73e79], body
weight [34,78,80] energy expenditure [81e83], glucose homeostasis
[84e89], and gastrointestinal motility [90e93]. Peripheral ghrelin or
GHRP-2 administration reliably induces the sensation of hunger and
increases food intake in lean, obese, healthy and malnourished in-
dividuals [94]. Interestingly, iv administration of ghrelin in healthy
volunteers increases neural activity in speciﬁc brain regions in
response to pictures of food. Endogenous fasting ghrelin is positively
related to hunger-modulated activity in the hypothalamus, amygdala,
and prefrontal cortex in response to palatable food stimuli [95,96].
Activation of these reward centers by ghrelin suggests enhancement of
food consumption is a more complex mechanism than the physical
sensations of hunger or satiety [97,98]. Interestingly, these ghrelin-
brain activity relationships are absent in women with anorexia nerv-
osa, suggesting the possibility of CNS-regulated ghrelin resistance in
these individuals [95].
4.2. Clinical pharmacology studies on ghrelin’s effect on the GH-
Axis
In humans, a single intravenous (iv) injection or a continuous 24 h
ghrelin infusion induces acute GH release [99,100] and increases 24 h
pulsatile GH secretion [101]. The importance of ghrelin in GH regulation
is supported by the observation that abnormalities of GHSR function
may be associated with familial short stature [102]. The GHSR locus is
one of the top sites suggested to contribute to the genetic variation of
height [103]. Several studies have assessed the association of ghrelin
and GHSR single nucleotide polymorphisms (SNPs) with height under
conditions of obesity and diabetes [reviewed in [104]]. At high doses,
ghrelin also increases levels of adrenocorticotropic hormone (ACTH),
prolactin, and cortisol levels [70], while it inhibits levels of luteinizing
hormone (LH) [105]. These effects desensitize and normalize with
prolonged ghrelin (or ghrelin mimetic) treatment [45,106]. Further-
more, ghrelin mimetics have been investigated as diagnostic agents to
establish growth hormone deﬁciency [107] as well as a therapeutic
option for age-dependent GH decline and have yielded some potentially
beneﬁcial effects [80] (Table 1). Notably, whereas several clinical
Table 1 e Summary of ghrelin mimetics tested in clinical trials.
Compound Company Active/inactive Indication
Ghrelin mimetic
Pralmorelin Kaken Pharma
Sella Pharma
Approved
Approved
Diagnostic for GH deﬁciency
Macimorelin Aeterna Zentaris Phase III Diagnostic for GH deﬁciency
Anamorelin Helsinn Phase III Anorexia/Cancer Cachexia
Relamorelin Rhythm Phase IIb Diabetic gastroparesis
Ulimorelin Tranzyme Inactive Opioid induced constipation/GI
functions
Ipamorelin Helsinn Inactive GI functional disorders
Carpromorelin Pﬁzer Inactive Frailty in elderly
CP 464709 Pﬁzer Inactive Frailty in elderly
Tabimorelin Novo Nordisk Inactive GH deﬁciency
Ibutamoren Merck Inactive Frailty in elderly
Examorelin/
Hexarelin
Diverse Academic
sponsored studies
Inactive GH release
SM 130686 Sumitomo Inactive Growth hormone deﬁciency
LY 426410
LY 444711
Eli Lilly Inactive GH release
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studies support a role of ghrelin in regulation growth and height, mice
lacking GHSR, ghrelin or GOAT show no growth abnormalities. Whether
these discrepant results from mice and humans speaks for distinct
GH-release pathways as of today elusive.
4.3. Clinical pharmacology studies on ghrelin’s effect on glucose
metabolism
Both ghrelin and its receptor are widely expressed in multiple regions
of the brain [3,108,109] and in peripheral tissues, such as the intestine
[110], pituitary [111,112], kidney [108,113], lung [108,114], heart
[110,115,116], ovaries [108], and pancreatic islets [17,40]. Expression
in pancreatic islets is consistent with a series of human studies
showing increased plasma levels of glucose and decreased plasma
levels of insulin following ghrelin administration [84e86,88,89].
GHSRs are also expressed by a-cells of the pancreatic islet and likely
contribute to the ability of ghrelin to directly stimulate glucagon
secretion [117].
Ghrelin inhibits insulin secretion in most animal studies [118e121],
and blockade of pancreatic-derived ghrelin enhances insulin secretion
and ameliorates the development of diet-induced glucose intolerance
[122]. Supporting these data is the ﬁnding that plasma ghrelin and
insulin levels seem to be negatively correlated, as the two hormones
exhibit reciprocal changes during the day and during a hyper-
insulinemic, euglycemic clamp [37,123]. Furthermore, continuous
ghrelin infusion for 65 min suppresses glucose-stimulated insulin
secretion and impairs glucose tolerance in healthy individuals [124].
In line with this, pharmacological inhibition of GOAT improves glucose
disposal by stimulating the release of insulin [60]. The reciprocal
relationship of ghrelin and insulin is supported by epidemiologic
studies showing an inverse relationship between circulating ghrelin
levels and indexes of insulin resistance [39]. A single iv dose of ghrelin
signiﬁcantly increases plasma glucose levels followed by a reduction
in fasting insulin levels in lean [84] and obese subjects with or without
polycystic ovarian syndrome [87], suggesting inhibition of insulin
secretion. Intriguingly, ghrelin’s suppression of insulin secretion in
pancreatic b-cells is mediated by a non-canonical GHSR1a signaling
pathway in which Gai rather than Gaq is coupled to the receptor [125].
This modiﬁed signaling is dependent upon agonist mediated molec-
ular interactions between GHSR1a and somatostatin receptor
subtype-5 (SST5) and the formation of GHSR1a:SST5 heterodimers
[126]. Conversely, some studies suggest that ghrelin has positive
trophic activity, protecting from b-cell damage in experimental
models of type 1 diabetes [127,128]. However, the onset of type 1
diabetes is associated with decreased circulating ghrelin levels
[129,130].
4.4. Clinical pharmacology studies on ghrelin’s effect on GI-Motility
Very shortly after the discovery of ghrelin by Kojima and Kangawa,
ghrelin was also described by another group, who named it motilin-
related peptide because of its homology with motilin, a gut hormone
involved in the regulation of the migrating motor complex (MMC) with
effects on gastric emptying [131,132]. However, this group did not
describe the octanoylation of ghrelin. It was soon hypothesized that
ghrelin may mimic the effect of motilin on gastrointestinal motility.
When ghrelin is administered iv into healthy individuals, it induces the
MMC in the fasted state, inhibits gastric accommodation, and accel-
erates gastric emptying in the postprandial state [6,92,133,134].
Several clinical trials are currently investigating the potential of ghrelin
mimetics in the treatment of hypomotility disorders (diabetic gastro-
paresis, postoperative ileus), but none of these has been marketed so
far [135] (Table 1).
4.5. Rodent pharmacology studies on ghrelin’s effect on food
intake
Ghrelin is the only circulating hormone that, upon systemic and central
administration, potently increases adiposity and food intake [2]. Similar
to other GH secretagogues [136] the effect of ghrelin on adiposity is
GH-independent and involves neural circuits that control food intake,
energy expenditure, nutrient partitioning, and reward [3]. In the ARC, a
key hypothalamic center regulating food intake and satiety [42], ghrelin
increases the activity of Npy and Agrp expressing neurons while
inhibiting the activity of proopiomelanocortin (Pomc) neurons [3]. NPY
and AgRP are crucial for ghrelin’s effect on feeding behavior as ghrelin
fails to increase food intake in mice lacking both Npy and Agrp [137]. In
line with this notion, AgRP neuron-selective GHSR re-expression in
otherwise GHSR deﬁcient mice partially restores the orexigenic
response to administered ghrelin and fully restored the lowered blood
glucose levels observed upon caloric restriction [138]. Of appreciable
note, hyperphagia observed under pathophysiological conditions, such
as streptozotocin-induced diabetes, is mediated by increased ghrelin
release, which targets the ghrelin receptor on NPY and AgRP neurons
[139]. A crucial regulator of Npy and Agrp expression is the hypo-
thalamic homeobox domain transcription factor Bsx [140], which is
also essential for ghrelin’s ability to stimulate food intake [140].
4.6. Rodent pharmacology studies on ghrelin’s effect on adiposity
The increased adiposity induced by the central administration of
ghrelin involves the stimulation of key enzymes promoting fatty acid
storage, while genes controlling the rate-limiting step in fat oxidation
are decreased [141]. These actions of the brain ghrelin system on
adipose tissue are mediated by the sympathetic nervous system
independent of food intake or energy expenditure [141]. In addition to
its actions on lipid metabolism in adipose tissue, chronic central
infusion of ghrelin also increases plasma cholesterol levels, and more
speciﬁcally HDL, an effect that is consistent with the fact that mice
lacking both ghrelin and GHSR1a show lower plasma cholesterol levels
than wild type mice [142]. Ghrelin’s effects on adiposity, therefore, are
achieved through centrally and peripherally mediated signaling
mechanisms, including modulation of the hypothalamic melanocorti-
nergic system and the food intake independent modulation of pe-
ripheral genetic programs regulating lipogenesis [141,143].
4.7. Rodent pharmacology studies using genetically engineered
mouse models
4.7.1. Studies in mice with adult-onset ablation of ghrelin-
producing cells
The group of Joseph Goldstein and Michael Brown recently generated
transgenic mice in which the diphtheria toxin receptor is expressed in
ghrelin-secreting cells. Adult-onset ablation of ghrelin-producing cells
in these mice, following administration of diphtheria toxin, had no
effect on food intake and body weight, indicating that while ghrelin has
potent pharmacological effects on food intake, energy metabolism, and
body weight, it is not an essential endogenous regulator of those
endpoints [144].
Despite this ﬁnding, diet-induced obesity renders NPY/AgRP neurons
unresponsive to the stimulatory actions of ghrelin on food intake
[143,145], an effect that is reversed with diet-restricted weight loss
[146]. However, mice continue to gain adiposity on a high-fat diet
(HFD) [143]; thus, reinstatement of ghrelin sensitivity with diet-induced
weight loss may provide a physiological means to protect a higher body
weight set point established after prolonged HFD exposure. Moreover,
selective reduction of the expression of GHSR1a in the paraventricular
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nucleus of the hypothalamus (PVH) reduces body weight without
affecting food intake [147], which supports the idea of two parallel
ghrelin-responsive hypothalamic circuits that regulate food intake and
adiposity independently. As yet, the differences in these neural circuits
remain unknown.
4.7.2. Studies in ghrelin deﬁcient mice
In recent years, studies using genetically engineered mouse models in
which the function of the endogenous ghrelin system is altered either
by loss [19,148e153] or gain of function [61,154] have contributed
signiﬁcantly to our knowledge about the multiple facets of ghrelin
action. Results from these studies must be interpreted with caution,
however, as most have utilized mice of mixed background (mainly
S129/C57BL6J) and S129 favors a lean phenotype [155]. In one study,
ghrelin deﬁcient mice of mixed background were reported to have
lower body weight and fat mass, which might be attributed to an
observed increase in energy expenditure and locomotor activity [19].
Upon HFD exposure, these mice also show a lower respiratory quo-
tient, indicating a shift in the metabolic fuel preference toward higher
lipid utilization. While these data indicate that ghrelin promotes energy
conservation by increasing carbohydrate metabolism while promoting
fat storage in adipose tissue, other studies using mice of mixed
background show no overt changes in body weight, adiposity, or food
intake between ghrelin deﬁcient mice and wt controls under chow-fed
conditions [149,150]. However, when chronically exposed to a HFD,
especially beginning at an early age, these same mice show a clear
metabolic beneﬁt from ghrelin-deﬁciency. It should be noted that this
beneﬁt is not evident in mature, congenic knock out (ko) mice on a
pure C57BL/6J background [155]. The phenotype of loss-of-function
models for ghrelin depends on environmental conditions. Under sub-
thermoneutral conditions accompanied by fasting, ghrelin ko mice
become compromised and are unable to integrate sleep and ther-
moregulatory responses to metabolic challenges [156]. When chron-
ically challenged with a HFD, ghrelin deﬁcient mice show improved
glucose disposal and insulin sensitivity compared to wt controls [19].
When crossing ghrelin deﬁcient mice with leptin deﬁcient ob/ob mice
[157], double mutants retain the marked body adiposity phenotype of
ob/ob mice. However, the double mutants show a signiﬁcant decrease
in basal glucose and an increase in basal insulin levels, as well as
improved glucose tolerance and insulin sensitivity when stimulated
with a glucose or insulin challenge, compared to native ob/ob mice. In
addition, fasting glucose levels are normalized in the double mutants,
compared to ob/ob mice [157].
The lack of signiﬁcant changes in food intake in ghrelin deﬁcient mice
does not support a role for ghrelin as an essential ‘meal initiation’ or
‘hunger’ hormone. Nevertheless, HFD exposure of ghrelin deﬁcient
mice reveals physiological roles for ghrelin in regulating body weight
and adiposity, potentially through altering fat deposition and meta-
bolism by decreasing fuel efﬁciency and increasing fat oxidation.
Such improvements in body weight homeostasis might lead indirectly
to improvements in glucose homeostasis; in addition, ghrelin deﬁ-
ciency might directly improve glucose sensitivity and pancreatic beta
cell function. The effects of ghrelin on insulin sensitivity are at least
partly mediated by the central nervous system, and more speciﬁcally
by AgRP neurons within the ARC. Using a tamoxifen-inducible AgRP-
CreER(T2) transgenic mouse model that allows spatiotemporally-
controlled re-expression of physiological levels of ghrelin receptors
(GHSRs) in AgRP neurons of adult GHSR-null mice that otherwise lack
GHSR expression, it was found that AgRP neuron-selective GHSR re-
expression fully restored the lowered blood glucose levels observed
upon caloric restriction [138]. The restoration of glucose levels was
associated to glucagon rises and hepatic gluconeogenesis induction
[138]
4.7.3. Studies in GHSR deﬁcient mice
The orexigenic effect of ghrelin is speciﬁcally modulated through
GHSR1a, as exogenous ghrelin fails to promote food intake in mice
lacking this receptor [158] and in rats treated centrally with GHSR1a
antagonists [147]. Despite the well-described actions of ghrelin on NPY
and AgRP neurons, very little is known about the function of other
hypothalamic neuronal populations expressing the GHSR. These
include the ventromedial nucleus of the hypothalamus (VMH), dorso-
medial nucleus of the hypothalamus and medial preoptic area
[159,160]. Elucidating the function of these populations will highlight
the role of ghrelin as being more than simply a “hunger hormone.”
As in mice lacking ghrelin, mice deﬁcient for GHSR are protected from
diet-induced obesity (DIO) when fed a HFD. This might be explained, in
part, by a mild hypophagia and preferential utilization of fat as an
energy substrate in these mice [151,152]. Expression of GHSR anti-
sense RNA under the TH promoter in the ARC of rats results in
hypophagia and decreased body weight and body fat [161]. Compared
to wt littermate controls, GHSR deﬁcient mice also show improved
glucose disposal and insulin sensitivity upon HFD exposure. However,
body weight and fat mass are not affected when male GHSR deﬁcient
mice are maintained on a standard chow diet [151,158]. Consistently,
ablation of ghrelin receptor reduces adiposity and improves insulin
sensitivity during aging by regulating fat metabolism in white and
brown adipose tissues [25]. The effects of ghrelin on glucose meta-
bolism during aging might be associated to GH levels, as it is known
that circulating GH levels, which cause insulin resistance [162], are
decreased in later stages.
Interestingly, simultaneous deletion of both ghrelin and GHSR results in
lower body weight and fat mass even when the double mutant mice
are fed a standard chow diet [153]. One possible explanation for this
ﬁnding is the potential existence of additional ligands for the GHSR
and/or additional receptors for ghrelin, which may exacerbate the
metabolic phenotype of double mutant mice where ghrelin and GHSR
are inactivated [153].
Another possibility is that GHSR may affect food intake independently
of ghrelin signaling, e.g. by heterodimerization with other receptors
such as the dopamine receptor [163] or GPR83 [164]. Of note, the
impact of GHSR signaling on food intake, body weight, or energy and
glucose homeostasis might be inﬂuenced by the receptor’s intrinsic
constitutive activity [165], thus complicating the direct comparison of
metabolic phenotypes of ghrelin and GHSR deﬁcient mouse models.
However, given the level of GHSR1a expression found in native tissues,
it is doubtful that basal activity is a contributing factor. Furthermore,
this interpretation might be confounded by the observation that
GHSR1a, but not ghrelin, is essential for appetite regulation by dopa-
mine receptor subtype-2 [166].
4.7.4. Studies in GOAT deﬁcient mice
Generation of mice with the genetic inactivation of GOAT also has
proven to be a useful tool to assess the role of des-acyl ghrelin without
in vivo octanoylation [20,61,167]. Work by the laboratories of Joseph
Goldstein and Michael Brown in young fat-depleted GOAT ko mice
showed that acyl-ghrelin is of crucial importance for preventing life-
threatening events of hypoglycemia under conditions of acute caloric
restriction, an effect attributable to ghrelin’s ability to promote the
release of GH from the anterior pituitary [20,168,169]. Accordingly,
when body fat is reduced by caloric restriction, ghrelin stimulates GH
secretion, which allows maintenance of glucose production, even
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when food intake is eliminated. In line with this role of ghrelin to
prevent hypoglycemia, adult-onset ablation of ghrelin producing cells
induces profound hypoglycemia during prolonged caloric restriction
[144]. Moreover, severe caloric restriction substantially increases
plasma GH levels and promotes hepatic autophagy in wt mice, allowing
the mice to maintain viable levels of blood glucose while lethal hy-
poglycemia and a blunted GH increase is observed in mice deﬁcient for
GOAT [170]. Hypoglycemia is also observed in GHSR-null mice
following the same prolonged caloric restriction protocol [138] and
upon initiation of acute caloric restriction of both ghrelin ko and GHSR
ko mice, although both genotypes adapted after 14 days [155]. Also
pharmacological inhibition of GOAT has been shown to improve
glucose disposal and to enhance insulin secretion, an effect notably not
seen in GHSR ko mice [60].
4.8. FTO and ghrelin
Several SNPs within the ﬁrst intron of the fat mass and obesity-
associated gene (FTO) are robustly associated with increased BMI
and adiposity across different ages and populations [171e176].
Subjects homozygous for the obesity-risk (A) allele of SNP rs9939609
have a 1.7-fold increased risk for obesity and exhibit overall increased
ad libitum food-intake [177e179], particularly fat consumption
[177,179e181], and impaired satiety [182,183] compared to subjects
homozygous for the low-risk (T) allele. Recently, a series of studies
implicated ghrelin in mediating this altered feeding behavior. In two
independent cohorts of normal-weight, adiposity-matched individuals
with either FTO rs9939609 TT or the obesity risk AA genotype [184],
AA subjects exhibited attenuated post-meal suppression of both
hunger and circulating acyl-ghrelin levels. Using fMRI, these studies
demonstrated that FTO rs9939609 genotype modulated the neural
responses to food images in homeostatic and reward brain regions.
Furthermore, AA and TT subjects exhibited divergent neural respon-
siveness to circulating acyl-ghrelin within brain regions that regulate
appetite, reward-processing and incentive motivation. At the molecular
level, FTO directly demethylates N6-methyladenosine (m6A), a naturally
occurring adenosine modiﬁcation in RNA and ghrelin mRNA has been
identiﬁed as an FTO target [184,185]. FTO over-expression in MGN3-1
cells, a validated ghrelin cell line, reduced ghrelin mRNA m6A
methylation, increased ghrelin mRNA abundance and the synthesis
and secretion of acyl-ghrelin. Furthermore, subjects with the A allele of
rs9939609 exhibit increased FTO expression [184,186] and decreased
ghrelin m6A methylation coupled with increased ghrelin expression
[184]. Interestingly, FTO also regulates the m6A methylation and
expression of key molecular components of the mid-brain dopami-
nergic system, which is known to play a key role in mediating the
rewarding effects of ghrelin [187]. Altered dopaminergic signaling may
account for the altered neural ghrelin sensitivity reported in rs9939609
FTO AA subjects [184]. This suggests that the known actions of acyl-
ghrelin, increased food intake, increased adiposity, preference for
high-fat food, enhanced operant responding for food rewards, induced
conditioned place preference for food rewards and a role in cue-
potentiated feeding are strikingly similar to the feeding phenotype of
rs9939609 AA subjects. However, while these ﬁndings of altered
ghrelin function in FTO rs9939609 AA subjects provide a parsimonious
explanation for the obesity risk phenotype seen in these subjects, given
the pleiotropic effects of FTO a number of other mechanisms could also
be implicated.
4.9. Additional functions of ghrelin
In addition to ghrelin’s role in glucose and energy homeostasis,
research over the last 15 years has revealed a surprising variety of
additional physiological functions of ghrelin in areas as distinct as
learning and memory [188e190], psychological stress, mood and
anxiety [191,192], depression [26,193,194], thymopoiesis [195],
sleep/wake rhythm [7e9,196,197], and aging [198,199]. Recent
pharmacological intervention trials also point to a neuroprotective role
of ghrelin in neurodegenerative diseases (e.g., Parkinson’s disease)
[198,199]. The ghrelin system’s neuroprotective effects are apparent
in mouse models of chronic psychosocial stress, wherein stress-
induced decreases in adult hippocampal neurogenesis become
exaggerated in mice lacking GHSRs [200]. Additional studies exam-
ining the genetic and pharmacological modulation of the ghrelin sys-
tem will help elucidate these novel roles of ghrelin.
5. GHRELIN ACTION IN THE BRAIN
5.1. Hypothalamic effects of ghrelin on energy metabolism
Although an important site of action of ghrelin on the control of food
intake is the ARC, ghrelin administration into other hypothalamic sites,
including the PVH [201,202] and the lateral hypothalamus [203] also
promote a positive energy balance. In the hypothalamus, ghrelin
triggers endocannabinoid release [204], leading to activation of the
calcium/calmodulin-dependent protein kinase 2 (CaMKK2) and
increased phosphorylation of the energy sensor AMP-activated protein
kinase (AMPK) [205e207]. Ghrelin mediated activation of GHSR1a also
triggers hypothalamic sirtuin 1 (Sirt1) [208,209], which deacetylates
p53, leading to increased phosphorylated levels of AMP-activated
protein kinase (AMPK) [206] and to the inactivation of enzymatic
steps of de novo fatty acid biosynthetic pathway in the VMH [207].
These molecular events induce changes in uncoupling protein 2 (UCP2)
[210] and the upregulation of the transcription factors Bsx [140],
forkhead box O1 (FoxO1), and cAMP response-element binding protein
(pCREB) [211] followed by subsequent activation of downstream
signaling pathways. Within the hypothalamus, ghrelin increases
expression of the prolyl carboxypeptidase (PRCP) a negative regulator
of the melanocortin 4 receptor agonist a-melanocyte stimulating
hormone (a-MSH) [212] and the mechanistic target of rapamycin
(mTOR) in the ARC. In fact, central inhibition of mTOR signaling with
rapamycin decreases ghrelin’s orexigenic action [213].
5.2. Non-hypothalamic effects of ghrelin on energy metabolism
Ghrelin also promotes a positive energy balance when administered to
non-hypothalamic sites such as the hindbrain [214e216] and limbic/
paralimbic regions including the amygdala [202,217,218]. A recent
study employed a genetically-engineered mouse model with Ghsr
expression limited to the hindbrain to determine if such site-selective,
hindbrain GHSR expression is sufﬁcient to mediate ghrelin’s actions on
food intake and blood glucose [219]. When these animals were pro-
vided food ad libitum, hindbrain-speciﬁc GHSR expression was not
sufﬁcient to permit the characteristic orexigenic response to subcu-
taneous ghrelin administration that is observed in wt animals. With
respect to the modulation of glucose homeostasis, hindbrain GHSR
expression was sufﬁcient to defend against the exacerbated fasting-
induced fall in blood glucose that is otherwise observed in mice with
global GHSR deﬁciency. These data help clarify the relevant sites of
ghrelin receptor action in the brain in the modulation of food intake and
blood glucose and complement a prior study investigating the effects
of tyrosine hydroxylase-Cre-driven GHSR expression, in which GHSR
expression occurs selectively in catecholaminergic (predominantly
dopaminergic) neurons, such as those in the VTA [28]. Notably, and
unlike with paired mesoderm homeobox 2B (Phox2b) cre-driven
hindbrain GHSR expression, catecholaminergic GHSR expression is
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sufﬁcient to partially rescue ghrelin-stimulated acute food intake, while
fully restoring the ability of administered ghrelin and chronic stress to
modulate food reward [28]. Also, unlike with the hindbrain-selective
GHSR expression, fasting blood glucose levels are not rescued by
selective GHSR expression in catecholaminergic cells [28].
Several lines of evidence indicate that the brainstem contributes to
ghrelin’s orexigenic action, as peripheral administration of GHSs and
intracerebroventricular (icv) ghrelin administration increase c-Fos
expression in the nucleus tractus solitaris and the area postrema
[220,221]. The role of the vagus nerve in the regulation of ghrelin-
induced food intake is more controversial, however, as one study
shows that blockade of gastric vagal afferents diminishes ghrelin’s
effect on food intake and decreases ghrelin induced c-Fos expression
in the ARC [222], while another study reports that gut vagal afferents
are not necessary for the hyperphagic action of ghrelin [223]. As
gastrectomy is accompanied by vagotomy, the fact that ghrelin analogs
are anabolic when given after gastrectomy suggests that the vagus is
not essential for ghrelin’s orexigenic effects [224,225].
5.3. Ghrelin and the reward system
Ghrelin engages reward neurocircuits that are activated by drugs of
abuse [15,226e232]. In particular, the central ghrelin signaling sys-
tem seems to be important for the rewarding properties of alcohol
[228], nicotine [233,234] and cocaine [235]. One of the neurocircuits
involved in these effects is the mesolimbic, dopaminergic pathway that
projects from the VTA to the nucleus accumbens (NAc) [229,236], a
pathway with a key role in reward-seeking behavior. Acting on this
pathway, ghrelin affects the motivation and drive to eat. Ghrelin
administration to the VTA and the NAc increases both food intake
[232,237] and extracellular dopamine [13,238]. Underscoring the
importance of dopamine for ghrelin’s orexigenic effects is the ﬁnding
that intra-VTA delivery of a ghrelin antagonist blocks the ability of
parenteral ghrelin to increase feeding [239]. Dopamine modulates the
incentive salience of food [240] and the animal’s willingness to work
for food [241]. In short, it increases feeding by increasing the drive,
arousal, foraging, and motor hyperactivity that occur during food
anticipation. For example, ghrelin ko mice do not show the normal
anticipatory locomotion to scheduled meals [242,243]. Ghrelin also has
direct effects on two other regions implicated in the control of feeding:
the hippocampus and amygdala, where it facilitates learning and
memory [188] and emotional arousal [244] and cue-potentiated
feeding [189].
GHSR1a and dopamine receptor-2 (D2R) are present as GHSR1a:D2R
heterodimers in native hypothalamic neurons and the inhibitory effects
of D2R signaling on food intake is dependent on the presence of
GHSR1a. GHSR ko mice and wt mice treated with a selective GHSR1a
antagonist are resistant to the anorexigenic effects of a DRD2 agonist.
Remarkably, ghrelin ko mice are fully sensitive to DRD2 agonist
suppression of food intake, demonstrating a dependence on GHSR1a
but not on ghrelin [163]. At the level of the VTA, but not the NAc, ghrelin
increases motivation for food, reﬂected by an increased lever pressing
for sucrose pellets in a progressive ratio task [231]. Interestingly, the
VTA-driven effects of ghrelin on food motivation involve different
neurocircuits than those involved in food intake. NAc delivery of
dopamine receptor (D1R and D2R) antagonists blocked the effects of
intra-VTA infused ghrelin on food motivation/reward behavior but not
food intake, suggesting that the VTA-NAc dopamine reward pathway is
important for food motivation but not food intake [245]. Given that
central blockade or stimulation of the dopamine receptors 1, 2, and 3
suppress the effects of icv delivered ghrelin on food intake [246], it can
be inferred that dopamine has a role outside of this classic reward
pathway to regulate ghrelin’s orexigenic effects. Consistent with this,
GHSR1a and D2R have been shown to interact within hypothalamic
neurons blunting the anorexigenic actions of D2R agonism [163].
Divergence in the mesolimbic circuitry mediating ghrelin’s orexigenic
versus and food reward effects also occur at the VTA level and can be
parsed using opioid and NPY Y1 receptor antagonists [232,236]. In-
teractions between ghrelin and the opioid system occur not only in the
mesolimbic dopamine system but also in the hypothalamus. More
precisely, GHSR1a and kappa opioid receptor colocalize in hypotha-
lamic areas and the blockade of the kappa opioid receptor in the ARC is
sufﬁcient to blunt ghrelin-induced food intake [247]. Collectively,
studies linking ghrelin to the mesolimbic reward circuitry suggest that
ghrelin’s role in hunger and meal initiation may extend to reward-
driven behaviors, including food motivation.
5.4. The role of ghrelin learning and memory performance
Ghrelin exhibits dense receptor expression in the hippocampus [188],
where it has been found to forms of learning and memory performance
in rodents. For example, ghrelin administration has been shown to
promote long term potentiation in the hippocampus, increase spine
density of neurons in the hippocampal CA1 region, and enhance
performance in several types of hippocampal-dependent learning and
memory tasks [188,248]. Additionally, ghrelin has been shown to in-
crease survival and reduce cell death of hippocampal neurons
following ischemia/reperfusion injury [249]. Finally, it was recently
shown that ghrelin cells receive direct synaptic input from the su-
prachiasmatic nucleus and the lateral geniculate nucleus, suggesting
that ghrelin is implicated in mediating circadian and visual cues for the
hypothalamic arousal system [250]
6. REGULATION OF GHRELIN SECRETION
Despite a growing body of literature characterizing ghrelin action and
the distribution of ghrelin cells, relatively little is known about the exact
molecular pathways responsible for the biosynthesis and release of
ghrelin. Instead, most of what is known regarding the control of
circulating ghrelin is on a broader, systemic level.
6.1. Ghrelin secretion in response to fasting and feeding
It has been known for several years that ghrelin levels rise pre-
prandially and decrease to baseline levels within the ﬁrst hour after
a meal [37], a pattern that can be entrained by artiﬁcial meal schedules
[251]. The magnitude of ghrelin reduction is proportional to the caloric
load and macronutrient content, and ingested lipids are the least
effective suppressor of plasma ghrelin [252]. Also, it is well established
that plasma levels of both acyl and des-acyl ghrelin rise with prolonged
food deprivation, increases that can be blocked by reserpine, which
depletes adrenergic neurotransmitters from sympathetic neurons
[253]. Sham feeding also suppresses ghrelin levels [254]. Further-
more, the recovery of ghrelin levels does not seem to be an important
determinant of intermeal intervals [255], and mice that lack ghrelin
have normal meal intervals.
6.2. Ghrelin levels in pathological conditions
It is well established that ghrelin plays a role in long-term energy
balance regulation, defending against prolonged energy deﬁciency.
Accordingly, in humans, circulating ghrelin levels are generally
inversely associated with weight gain, adiposity, and insulin resistance
[256] and positively correlated with weight loss induced by exercise,
low-calorie diet, mixed life-style modiﬁcation, anorexia nervosa and
cachexia due to chronic obstructive lung disease (COPD) or chronic
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heart failure (CHF) [71,257,258]. Ghrelin levels are low in obesity [259]
and even lower in obese binge eaters [260], suggesting that, in these
instances, ghrelin is a consequence rather than a cause of overeating.
In line with the observation that ghrelin levels increase by fasting,
plasma levels of ghrelin are high in patients with cachexia or in patients
with eating disorders such as anorexia nervosa and bulimia nervosa
[as reviewed in [166,258,261]]. Interestingly, extreme fasting reduces
ghrelin levels in healthy subjects [262e264]. These effects are pre-
vented by subdiaphragmatic vagotomy and, separately, by adminis-
tration of the anticholinergic agent, atropine [265]. Conversely, obese
patients with Prader-Willi syndrome are hyperphagic and have very
high circulating ghrelin levels [266,267]. Elevated levels of ghrelin are
further reported from patients with Hashimoto’s Thyroiditis [268] but
not from overweight/obese patients with Bardet-Biedl syndrome [269],
Cushing’s Disease [270,271], or HIV-Lipodystrophy [272]. Taken
together, these data suggest that changes in circulating plasma levels
of ghrelin may be relevant for the increase in adiposity in humans,
although the degree of its contribution remains to be determined.
6.3. Ghrelin levels after bariatric surgery
Recent data demonstrate variable effects of various bariatric surgery
procedures (i.e. Roux-en-Y gastric bypass, vertical sleeve gastrectomy,
laparascopic adjustable banding) on ghrelin levels (generally demon-
strating decreases post-surgery) [273e279], shedding light on how
ghrelin exerts its mechanistic effects in the gastrointestinal tract
(reviewed in [280]). Low ghrelin levels have been reported for in-
dividuals after weight loss induced by Roux-en-Y gastric bypass,
initially believed to play a key role in the decreased appetite observed
after this surgery [257]. Subsequent data, however, show that ghrelin
levels rise within the ﬁrst year after this surgery in humans [281] and
within 6 weeks after surgery in mice [282]. Additionally, compared to
wt control mice, in ghrelin ko mice, vertical sleeve gastrectomy is
equally efﬁcient in lowering body weight [283], indicating a ghrelin
independent effect in this type of bariatric surgery.
6.4. Ghrelin secretion in response to external food cues
Ghrelin release during fasting is mediated via activation of the auto-
nomic nervous system. There is evidence that both cholinergic and
adrenergic neurotransmission are involved in the release of ghrelin.
Stimulation of ghrelin release in response to cholinergic activation by
pharmacological substances or sham-feeding has been reported in
humans and rodents [284e286]. In addition, food deprivation-induced
elevation of plasma ghrelin levels is driven by an increased vagal
efferent tone [284,285]. However, these results are not conﬁrmed by
in vitro studies either in a ghrelinoma cell line [287] or primary cell
culture from rat stomach [288].
External food cues such as sight, smell, and taste trigger the cephalic
phase of ingestive behavior, which consists of increased gut motility,
gut hormone secretion, and autonomic arousal [289]. This response, in
turn, triggers central arousal and incentive mechanisms that promote
food consumption. The cephalic response includes ghrelin release,
which increases after exposure to food cues in humans [290].
Conversely, recent evidence suggests that anticipation of the caloric
content of an investigator-supplied milkshake modulates the post-
prandial reduction in ghrelin levels [291]. When subjects believed
they were consuming a high calorie rather than a “healthy” milkshake,
their ghrelin levels were much more reduced. In sum, ghrelin secretion
is part of a CNS-gut control loop for feeding; food cues promote ghrelin
release from the stomach, which feeds back to the CNS to activate
hypothalamic and dopaminergic feeding centers. This feedback allows
other factors such as chronic stress, negative energy balance, leptin
and insulin to affect motivation to feed by enhancing or reducing the
cephalic release of ghrelin [290,292].
6.5. Suppression of ghrelin secretion
There has been signiﬁcant interest in unveiling the mechanisms
involved in postprandial suppression of circulating ghrelin levels. The
placement of a pyloric cuff in rats to block normal ﬂow of gastric
contents into the duodenum prevents drops in circulating ghrelin
usually observed following intragastric infusion of glucose [293].
Furthermore, stomach distention by infusion of water into animals
whose gastric outﬂow was occluded at the level of the pylorus also
was ineffective in changing ghrelin levels [294]. Thus, it appears that
neither nutrient detection by the stomach nor gastric distention is
sufﬁcient for eliciting the usual postprandial fall in circulating ghrelin.
On the other hand, both intraduodenal and intrajejunal administration
of nutrients via intestinal cannulas lower circulating ghrelin levels.
Within the stomach, considered the predominant source of circulating
ghrelin, ghrelin cells tend to cluster towards the base of the gastric
mucosal glands and are of the round, closed-type variety that do not
have direct contact with gastric luminal contents (reviewed in [295]).
There is also credible evidence that ghrelin cells exist, although in
fewer numbers, throughout the entirety of the gastrointestinal tract,
including the duodenum, where more elongated, opened-type ghrelin
cells, which have direct contact with the intestinal lumen and may be
regulated differently than their gastric counterparts.
6.6. Ghrelin secretion in response to dietary macronutrients
A recent randomized, within-subjects crossover human trial helped
characterize the manner in which different types of nutrients inﬂuence
the pattern of postprandial ﬂuctuations in plasma ghrelin levels [296].
For this study, isocaloric, isovolemic beverages, composed primarily of
carbohydrates, proteins, or lipids, were administered to volunteers
whose plasma levels of acyl and total ghrelin were measured multiple
times over the next 6 h. The lipid drink was the least effective, and the
protein drink was most effective in lowering ghrelin levels. Although the
carbohydrate drink resulted in the largest drop in ghrelin initially, it was
the only drink to induce a subsequent rebound to above pre-prandial
levels. Interestingly, ghrelin levels are also suppressed by sham
feeding in humans [254], underscoring the role of the cephalic phase in
the modiﬁcation of ghrelin levels prior to and in response to a meal.
Animal data suggest that these nutrient-associated decreases in
circulating plasma ghrelin levels do not appear to involve the vagus
nerve [223], which relays interoceptive sensory information from the
viscera to the CNS and helps control visceral function. In fact, following
intragastric gavage of a liquid diet to animals that had undergone
subdiaphragmatic vagotomy, decreased ghrelin levels were observed
[265]. However, the vagus nerve does seem to play a role in the rise of
plasma ghrelin associated with a negative energy balance, as 48 h food
deprivation-associated elevations in circulating ghrelin are prevented
by subdiaphragmatic vagotomy or administration of atropine [265].
6.7. Hormones and neurotransmitter regulating ghrelin secretion
Recent studies have demonstrated that increases in ghrelin levels also
occur upon acute or chronic stress that is not necessarily related to
negative energy balance [reviewed in [26,28,297,298]]. Indeed,
sympathetic activation increases ghrelin secretion [192]. Both in vitro
and in vivo studies have demonstrated release of ghrelin in response to
sympathetic stimulation mediated viab1-adrenergic receptors present
on the ghrelin cell [253,284,287,288,299].
To more directly study the determinants of ghrelin secretion, a recent
study performed local infusion of candidate compounds into the gastric
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submucosa followed by measurement of ghrelin mobilization via
implanted microdialysis probes [300]. Using this method, epinephrine,
norepinephrine, endothelin, and secretin were found to stimulate
ghrelin release. In contrast to the stimulation of ghrelin release by
activation of the sympathetic nervous system (SNS), the inhibition of
ghrelin release seems primarily mediated by gastrointestinal hormones
released during nutrient digestion, such as somatostatin and gastrin
releasing peptide/bombesin. Numerous other hormones as well as
many neurotransmitters, neuropeptides, glucose, and amino acids had
no effect. Although this microdialysis technique and others, such as an
ex vivo stomach explant culture system [294,301], help focus on
locally acting compounds that inﬂuence ghrelin release, the techniques
do not discriminate between compounds that act directly on ghrelin
cells versus those that act indirectly via effects on neighboring cells. In
summary, the regulation of ghrelin release is a complex process that is
tightly controlled by both, the SNS and the gastrointestinal tract and
which involves hormonal stimuli not necessarily involved in energy
balance regulation. The observation that also factors not involved in
systems metabolism regulate ghrelin secretion speaks for a broader
physiological role of ghrelin and is in line with a multitude of ghrelin
effects beyond the regulation of hunger and satiety. A potential
beneﬁcial effect of this complexity is the possibility to target the ghrelin
system for the treatment of pathological conditions not necessarily
related to a negative energy balance, such as e.g. gastroparesis.
Recent studies showed that that the ghrelin cell is chemosensory and
contains taste receptors similar to those located in the tongue. Indeed,
the ghrelin cell is co-localized with the gustatory G-proteins, a-gust-
ducin and a-transducin. Studies in a-gustducin ko mice show that a-
gustducin partially mediates the effect of bitter tastants on ghrelin
release [302]. Similarly, the taste 1 receptor subtype, TAS1R3,
involved in sensing both sugars and amino acids, is co-localized with
ghrelin cells in the antrum [303]. The closed-type ghrelin cells in the
stomach may receive chemosensory input from the bloodstream while
the opened-type cells in the duodenum may respond to luminal stimuli.
The long-chain fatty acid sensing receptor GPR120 is co-localized with
ghrelin containing cells in the duodenum but not in the stomach and
has been shown to play a role in the lipid-sensing cascade of the
ghrelin cell [68]. Free fatty acid receptor 1 (FFAR1), involved in sensing
of long/medium chain fatty acids, is expressed only in the des-acyl
(non-active)-containing ghrelin cell population in the stomach, and
its function is unclear [68]. More studies are warranted to elucidate the
role of taste receptors in the effects of nutrients on ghrelin secretion.
It is likely that recent ﬁndings and new tools will provide greater insight
into the regulation of ghrelin secretion (as reviewed in [304]). For
instance, the development of novel, high-throughput sandwich enzyme
linked immunosorbent assays or radioimmunoassays for the speciﬁc
and sensitive detection of acyl-ghrelin as well as new mass spec-
trometry methods will permit accurate means to detect the different
forms of circulating ghrelin and determine how various manipulations
inﬂuence the levels of these different forms [305].
Another key development is the identiﬁcation of GOAT, the enzyme
responsible for catalyzing ghrelin’s unique post-translational modiﬁ-
cation [56,57]. Recent work involving genetic manipulations of GOAT
expression and the aforementioned mass spectrometry methods are
challenging some of the accepted dogma about ghrelin secretion and
regulation and suggest that ghrelin acylation and the secretion of
acylated ghrelin represent two independent processes [61].
6.8. Ghrelin secretion regulated by G-protein coupled receptors
Over the last few years, several new ghrelin secretion models have
been developed. Quantitative PCR analysis of FACS-puriﬁed gastric
ghrelin cells identiﬁed a series of G-protein coupled receptors (GPCRs)
that regulate ghrelin secretion. The GPCRs stimulating ghrelin secre-
tion were mainly Gs-coupled and include the b1-adrenergic receptor,
the GIP receptor, the secretin receptor (SCTR) and, interestingly, the
sensory neuropeptide receptor CGRP, and the melanocortin 4 receptor
(MC4R) [306]. GPCRs inhibiting ghrelin release were Gq and/or Gi
coupled and included the somatostatin receptors (SSTRs), the lactate
receptor (GPR81) and receptors for short chain fatty acids (FFAR2) and
long chain fatty acids (FFAR4) (Figure 4) [306].
6.9. Models to assess ghrelin secretion using transgenic mice
Other models developed to assess ghrelin secretion include
genetically-engineered mouse models in which green ﬂuorescence
Figure 4: Schematic overview of the 7TM receptors judged to be either stimulating (in green to the right) or inhibiting (red or orange to the left and top) ghrelin secretion directly on
the ghrelin cell. The main signaling pathway (Gas or Gai) employed by each of the receptors in the ghrelin cell is indicated inside the receptor in black. Figure taken from Engelstoft
et al., Mol Metab. 2013 [303].
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protein reports on the location of ghrelin-expressing cells. This method
enables direct visualization of ghrelin cells, and ﬂuorescence activated
cell sorting-mediated isolation of ghrelin cells for expression analyses
and cell culture [295,307,308]. Primary cell cultures of dispersed
gastric mucosal cells from adult mice and 8-day-old rat pups also have
been developed to investigate ghrelin secretion [288,307,309].
Ghrelin-secreting immortalized cell lines developed from ghrelinomas
in the stomachs (SG-1, MGN3-1) and pancreatic islets (PG-1) of
transgenic mice expressing SV40 large T-antigen under the control of
preproghrelin promoter are now available [253,310]. These ghreli-
noma cell lines retain many of the key, phenotypic features of ghrelin
cells and respond to many of the same regulators of ghrelin secretion
that have been described in vivo and in primary culture systems
[253,288,307,310].
Using these models, the modulation of ghrelin release by peptide
hormones, monoaminergic neurotransmitters, glucose, fatty acids,
second messengers, potential downstream effector enzymes, and
channels has now been investigated. Insulin, glucagon, oxytocin, so-
matostatin, dopamine, glucose, and long-chain fatty acids all have
been shown to regulate ghrelin secretion through their direct inter-
action with ghrelin cells [253,288,307e310]. In addition, all of these
models, as well as related in vivo studies, have been used to conﬁrm
that the catecholamines norepinephrine and epinephrine act as direct
ghrelin secretagogues [253,287,288,299,307]. These data are sup-
ported by high levels of b1-adrenergic receptor expression in ghrelin
cells enriched from the stomach of ghrelin-green ﬂuorescent protein
reporter mice as well as in the SG-1 and PG-1 ghrelin cell lines [253].
Forskolin, a potent activator of adenlyl cyclase, mimics the effect of
norepinephrine [253], suggesting that activation of adenylyl cyclase
and an ensuing elevation of cAMP occurs following engagement of b1-
adrenergic receptors, as has been shown in other cell systems
[311,312]. Interestingly, neuronal and endocrine signals have stimu-
latory effects on ghrelin secretion whereas paracrine signals and
macronutrient metabolites such as fatty acids inhibit ghrelin release
[306].
Altogether, these ﬁndings, along with the aforementioned microdialysis
experiments, link fasting-induced stimulation of the sympathetic ner-
vous system and ensuing release of norepinephrine locally in the
stomach wall to the release of ghrelin [168,299]. New transgenic and
cell culture models should allow for many more discoveries in the
regulation of ghrelin secretion and other aspects of ghrelin cell
physiology. In summary, recent studies reveal a comprehensive picture
of the receptor repertoire expressed on the ghrelin cells, which allows
for deeper analyses of the physiological properties and pharmaco-
logical potential of the ghrelin cell.
7. OPEN QUESTIONS
7.1. What is the role of des-acyl ghrelin?
7.1.1. Enzymes regulating des-acylation of ghrelin
Depending on the species, the serum half-life of acyl-ghrelin varies
between 240 min in humans and 30 min in rats [313]. The differences
in ghrelin’s half-life might be explained by the fact that the enzymes
responsible for the des-acylation and cleavage of ghrelin differ
remarkably across species. Butyrylcholinesterase is the predominant
enzyme responsible for ghrelin inactivation in humans whereas car-
boxylesterases allow for an eight times faster ghrelin des-octanoylation
in rodents [313]. In rodents, des-octanoyl ghrelin is localized in two
ghrelin cell populations in the stomach: cells that contain only des-
octanoyl ghrelin and cells that contain both des-octanoyl and
octanoyl ghrelin [302,314]. Most studies have analyzed both des-acyl
and acyl ghrelin ﬁnding that the majority of ghrelin in circulation is des-
acylated. No receptor for des-acyl ghrelin has been identiﬁed and a
recent study in which acyl ghrelin was assessed in human plasma
using mass spectrometry suggests that all ghrelin in circulation is
acylated and that des-acyl ghrelin may be an artifact of sample
handling [315].
7.1.2. Effects of des-acyl ghrelin
Nevertheless, several studies suggest that des-acyl ghrelin promotes
differentiation and fusion in C2C12 skeletal muscle cells [29], prevents
muscle atrophy [30], elicits GHSR1 independent effects on energy and
glucose metabolism [316e318], and exerts a cardioprotective effect
on endothelial cells and cardiomyocytes [319,320]. Central infusion of
des-acyl ghrelin into the third ventricle of rats increases short-term
food intake, whereas peripheral administration of des-acyl ghrelin
seems to have no direct effect on food intake [317]. The effect of des-
acyl ghrelin on food intake is independent of GHSR1a and Npy
signaling and might be orexin mediated [317]. Other studies, however,
suggest that des-acyl ghrelin decreases food intake in rats and dis-
rupts stomach motor activity under conditions of fasting [321].
Transgenic mice overexpressing des-acyl ghrelin have reduced body
fat mass when fed a regular chow diet and are protected from diet-
induced obesity when challenged with a HFD [321]. Although there
are speculations about a potential receptor for des-acyl ghrelin located
in the cardiovascular system [320], to date no such receptor has been
identiﬁed.
Growing evidence points to a GHSR1a-independent role of des-acyl
ghrelin in glucose metabolism, possibly antagonizing the effect of
acyl-ghrelin. The often reported increase of plasma glucose levels
and decrease of plasma insulin levels upon ghrelin administration
[84e86,88,89] seem to be antagonized by co-administration of des-
acyl ghrelin [322]. Several human studies report a positive relation-
ship between des-acyl ghrelin and insulin sensitivity [323,324],
although other studies do not support this ﬁnding [325]. The effect of
des-acyl ghrelin on glucose metabolism might be triggered indirectly
via modulation of lipid metabolism, as transgenic mice overexpressing
des-acyl ghrelin have lower body fat mass, lower body weight gain,
and improved insulin sensitivity compared to wt controls [318,326].
Furthermore, administration of des-acyl ghrelin decreases activation of
gene programs regulating lipogenesis [327]. A more recent study in
mice shows that chronic, subcutaneous administration of des-acyl
ghrelin prevents the typical metabolic alterations caused by chronic
HFD exposure, such as increased expression of pro-inﬂammatory
cytokines and the development of HFD-induced glucose intolerance
and insulin resistance [328]. Conversely, mice overexpressing ghrelin
driven by the neuron-speciﬁc enolase (NSE) promoter develop age-
related glucose intolerance despite having lower body weight [18].
Recent observations suggest a direct role on glucose metabolism
based on observations indicating that des-acyl ghrelin promotes sur-
vival of pancreatic b-cells and as des-acyl ghrelin prevents the dia-
betogenic effect of streptozotocin [329e332]. Other data suggest that
des-acyl ghrelin administered centrally to mice at high pharmacolog-
ical doses acts to increase adiposity and glucose-stimulated plasma
insulin through a GHSR-dependent mechanism [333].
7.2. Is ghrelin a ‘hunger’ hormone?
Ghrelin levels rise pre-prandially, and administered ghrelin reliably
increases food intake in humans and rodents [2,94], supporting a role
for ghrelin in hunger, meal initiation, and feeding behavior in normal
physiology. The acute, orexigenic effects of ghrelin, however, are most
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profound when ghrelin is delivered centrally, perhaps reﬂecting more
widespread and simultaneous activation of diverse CNS sites. Indeed,
orexigenic effects are observed not only after parenchymal delivery to
the hypothalamic, brainstem and mesolimbic reward areas but also
when administered to brain areas with a less well-established role in
feeding control such as the amygdala [217], hippocampus [189] and
dorsal raphe nucleus [334]. Recruitment of diverse feeding pathways
by endogenous ghrelin may be under physiological control, perhaps
reﬂecting food availability and/or nutritional status. Consistent with
this, the ARC appears to show increased responsiveness to ghrelin in
fasted rats relative to fed rats [335], and more ghrelin appears to gain
CNS access in the fasted state [336].
It is not at all clear that ghrelin’s acute orexigenic and chronic pro-
obesity effects are coupled. While ghrelin may provide an acute
hunger signal in the pre-prandial period, there is little evidence to
suggest that sustaining high ghrelin levels induces hyperphagia in the
long term. Despite numerous studies showing increased food intake
upon acute or chronic systemic ghrelin application, mice deﬁcient for
ghrelin, GHSR or GOAT, nor transgenic mice overexpressing ghrelin
and/or GOAT show alterations in food intake compared to wt controls
[61,149,153]. Also, ghrelin antagonists, which were developed as anti-
obesity drugs, do not appear to have chronic anorexigenic properties
per se [337]. It may be helpful, therefore, to separate the suggested
role for ghrelin as a hunger-promoting hormone in normal physiology
from its therapeutically relevant, long-term obesogenic effects, which
may be less linked to feeding control.
The surge in ghrelin before a meal could be linked to another role for
ghrelin e to prepare the organism for incoming food in order to
metabolize and store energy efﬁciently [61]. In line with this, ghrelin
activation is inﬂuenced greatly by dietary lipids [61,63], and ghrelin
might signal to the brain that abundant calories are available to acutely
ﬁll the organism’s fuel stores.
One might argue that the typical increase of plasma ghrelin levels during
prolonged food deprivation and the increase of ghrelin before a meal
followed by the subsequent decrease afterwards clearly point to its role
as a ‘hunger’ hormone. However, as discussed, the surges in ghrelin
before a meal could also be explained by the theory that ghrelin prepares
the organism for incoming food in order to metabolize and store energy
efﬁciently [61]. In line with this, ghrelin activation is highly inﬂuenced by
dietary lipids [61,63], and, therefore, ghrelinmight signal to the brain that
abundant calories are available to acutely ﬁll the organism’s fuel stores.
The observation that ghrelin, independent of its effect on food intake,
stimulates genetic programs regulating lipogenesis [141,143] is in line
with this proposed role as a lipid sensor (as discussed in section 3.3).
7.3. Is the ghrelin receptor still a druggable target?
Ghrelin and its agonists appeal to those who desire to exploit the potent
anabolic biology of the hormone. Such attention is directed at cachexic
and frail states. Ghrelin has a very short half-life but the peptide can be
engineered for a more sustained delivery and better pharmacokinetic
properties. Treatment with ghrelin by infusion may be indicated in very
acute circumstances when a short-term anabolic state is desired, such
as prior to an elective surgery. The non-peptide GHSR1a agonists
developed prior to the discovery of ghrelin are orally bioavailable; most
importantly, they produce signiﬁcant exposure levels for up to 24 h.
The extended half-life of these compounds is of metabolic and func-
tional importance, because, in contrast to ghrelin, chronic adminis-
tration of non-peptide agonists results in sustained but modest
increases in GH and IGF-1 superimposed on endogenous GH/IGF-1
without an increase in cortisol [338]. Interestingly, in obese subjects
the anabolic effects of MK0677 produce an increase in the ratio of
lean/fat mass [339]. Chronic therapy with orally active stable GHSR1a
agonists may have utility in frail, elderly subjects because MK0677
rejuvenates the GH/IGF1 axis by enhancing pulse amplitude of episodic
GH release to match the physiological proﬁle of young adults [338].
This effect is consistent with rescue of the epigenetic-mediated age-
dependent decline in GHSR expression that reduces ghrelin sensitivity
[340]. Indeed, encouraging results were observed in elderly patients
recovering from hip fracture [341], with beneﬁcial effects on skeletal
muscle and bone density [80].
Other positive effects of ghrelin are reported in patients with cachexia,
sarcopenia (muscle wasting due to aging [342]), myopenia (muscle
wasting due to chronic illness [343]), and frailty states [343,344].
Among the ﬁrst applications of ghrelin in human chronic illness were
studies in CHF [34] and COPD [78,345]. A pilot study in 10 CHF patients
reported decreased levels of norepinephrine, improved cardiac func-
tion and exercise capacity [34]. In animal models using a placebo
control the cardiac effects could not be conﬁrmed [346], but these
models validated weight gain and the skeletal muscle anabolic effects
of ghrelin and ghrelin analogs [110,347,348]. Of interest, in CHF,
ghrelin secretion is modulated by application of brain natriuretic
peptide, which is produced in the heart and generally increased in
heart failure [349]. In advanced CHF, ghrelin resistance has been
observed [350]. The ﬁrst studies of ghrelin in COPD, focused on
cachexia [78]. Preliminary studies suggested that ghrelin increases
skeletal muscle mass and improves exercise capacity. In a recent
double-blind controlled trial, ghrelin improved symptom scores and
increased respiratory muscle strength [345]. An additional indication
for ghrelin treatment may be replacement therapy to patients who have
undergone total gastrectomy due to gastric cancer. Theoretically, this
is based on the fact that most ghrelin is produced in the stomach and
that total gastrectomy results in loss of appetite, body fat and also lean
body mass. Indeed, proof of concept studies in mice and humans have
yielded positive results [224,225].
Inhibition of GOAT-mediated ghrelin acylation is considered an inter-
esting opportunity to tackle obesity. Several GOAT inhibitors have been
developed [60,62], and their intraperitoneal administration promotes
weight loss while improving glucose tolerance in wildtype (wt) mice but
not in mice deﬁcient for ghrelin [60]. Ghrelin receptor agonists such as
BIM-28131 (a.k.a. RM-131) have sustained effects in increasing body
weight at long-term [351]. Chronic therapy with ghrelin agonists,
however, is associated with weight gain, fat attrition, and insulin
resistance. Such observations have led to drug discovery efforts
designed to block ghrelin action, inducing a negative energy balance
with a goal of treating obesity and insulin resistance. Although ghrelin
levels are lower in obesity, that circulating ghrelin levels increase
during a negative energy state may suggest that a method inhibiting
ghrelin activity may be useful for preventing weight regain after diet
and exercise (or another weight loss treatment) rather than as a weight
loss therapeutic. The greatest utility of des-acyl ghrelin, in fact, ap-
pears to be for the treatment of insulin resistance, but only when
injected in combination with ghrelin.
Several synthetic ghrelin mimetics are being pursued in clinical trials
for diverse indications (Table 1). Three compounds are currently in
development. Macimorelin is in clinical trials for the diagnosis of GH
deﬁciency, relying on the stimulation of the hypothalamic pituitary axis,
as described earlier in this review [352]. A second compound, Ana-
morelin, is in clinical trials for the treatment of cancer cachexia in the
treatment of non-small cell lung cancer. Anamorelin mechanistically
relies on the anabolic effects noted with ghrelin and ghrelin mimetics
[353]. Ghrelin and synthetic ghrelin mimetics can also stimulate gastric
emptying and can function as gastrointestinal prokinetics [354e357].
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While our understanding of the mechanism by which ghrelin elicits
these effects is still limited, a direct effect of the ghrelin agonist
Relamorelin has been shown on human and mouse fundus and
jejunum smooth muscle cells and human and rodent colonic circular
smooth muscle [357], where expression of the GHSR has been
described [358]. The ghrelin mimetic Relamorelin (also known as
RM-131) is being developed for the treatment of diabetic gastroparesis
[357], for which the compound is well tolerated, and has direct
beneﬁcial effects on gastric emptying, while reducing the incidence
of nausea and vomiting. Beneﬁcial effects have also been noted
for colonic motility disorders where prokinetic effects have been
demonstrated in humans in the colon [354]. Relamorelin is currently in
Phase II clinical trials for treatment of diabetic gastroparesis and other
gastrointestinal (GI) disorders [93]. In a rodent model of irritable bowel
syndrome, ghrelin [359] and synthetic ghrelin mimetics [93] show
improvements in tissue damage while modulating inﬂammatory re-
sponses. Synthetic ghrelin mimetics, therefore, may ﬁnd beneﬁcial
applications in diverse functional gastrointestinal disorders.
8. CONCLUSIONS
Since ghrelin was discovered in 1999, we have come a long way in
understanding ghrelin’s multifaceted nature. Numerous studies on
ghrelin’s physiological effects (Figure 3) have led us to new aspects of
human and animal physiology and revealed a complex system for
acylating hormones, which was previously unknown. The next era
should exploit this unique biology for diagnostic and therapeutic beneﬁt.
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